Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies

European Journal of Biochemistry

Volumn 268, Issue 10, 2001, Pages 2856-2866

  Zeder Lutz, Gabrielle ^a   Hoebeke, Johan ^a   Van Regenmorte, Marc H V ^a,b  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b CNRS   (France)

Author keywords

Antibody antigen interaction; HIV; Kinetics; Surface plasmon resonance

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOMER; OLIGOMER; RECOMBINANT ANTIGEN;

ANTIBODY AFFINITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; OLIGOMERIZATION; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE; VIRUS NEUTRALIZATION;

ANTIBODIES, MONOCLONAL; ANTIGENS; EPITOPES; HIV ENVELOPE PROTEIN GP160; HUMANS; KINETICS; MODELS, CHEMICAL; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SURFACE PLASMON RESONANCE; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034826583     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2001.02167.x     Document Type: Article

References (78)

1. Overview: Practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine
2. Why do we not have an HIV vaccine and how can we make one?
3. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
4. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: Performance criteria for selecting candidate antibodies for clinical trials
5. Prospect for prevention of human immunodeficiency virus infection: Purified 120-kDa envelope glycoprotein induces neutralizing antibody
6. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein
7. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120
8. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera
9. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
10. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
11. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site
12. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120
13. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
14. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
15. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody
16. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
17. Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology
18. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
19. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
20. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
21. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells
22. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
23. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains
24. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120
25. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies
26. Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site
27. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins
28. Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins
29. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
30. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
31. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates
32. Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules
33. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12
34. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1
35. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
36. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
37. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
38. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex
39. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
40. Antibody and virus: Binding and neutralization
41. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: Evidence for in vivo recombination and determinants of cytotropism outside the V3 domain
42. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain
43. Characterisation of a series of human immunodeficiency virus isolates derived sequentially from a single patient
44. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors
45. Epitope mapping on BIAcore: Theoretical and practical considerations. Methods: A companion
46. Active concentration measurements of recombinant biomolecules using biosensor technology
47. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors
48. Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1
49. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein
50. Real-time competitive kinetic analysis of interactions between low-molecular-weight ligands in solution and surface-immobilized receptors
51. Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein
52. Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence
53. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates
54. Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV
55. A peptide from the heptad repeat of human immunodeficiency virus gp41 shows both membrane binding and coiled-coil formation
56. Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41
57. Mutation-directed chemical cross-linking of human immunodeficiency virus type 1 gp41 oligomers
58. A trimeric structural domain of the HIV-1 transmembrane glycoprotein
59. Atomic structure of the ectodomain from HIV-1 gp41
60. Core structure of gp41 from the HIV envelope glycoprotein
61. Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain
62. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution
63. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
64. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
65. Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate
66. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
67. The antigenic structure of the HIV gp120 envelope glycoprotein
68. Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus
69. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
70. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
71. Analysis of synergism/antagonism between HIV-1 antibody-positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity
72. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120
73. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies
74. Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein
75. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1
76. The human immunodeficiency virus type 1 gp120, V2 domain mediates gp41-independent intersubunit contacts
77. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
78. Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: Functional complementation of specific defects in gp120 and gp41